EWTX
NASDAQ
US
Edgewise Therapeutics, Inc. - Common Stock
$33.33
▲ +$0.19
(+0.57%)
Vol 986K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.6B
ROE
-30.9%
D/E
0.00
Beta
0.26
52W
$11–$30
Wall Street Consensus
18 analysts · Apr 20266
Strong Buy
9
Buy
3
Hold
0
Sell
0
Strong Sell
83.3%
Buy Rating
Price Chart
Similar Stocks
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
LQDA
Liquidia Corp
$3.0B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
SUPN
Supernus Pharmaceuticals Inc
$2.8B
ALMS
Alumis Inc
$1.0B
Earnings
Beat rate: 75.0%
Next Report
May 06, 2026
EPS Estimate: $-0.50
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.50 | — | — |
| Dec 2025 | $-0.44 | $-0.47 | $-0.03 |
| Sep 2025 | $-0.41 | $-0.39 | +$0.02 |
| Jun 2025 | $-0.42 | $-0.34 | +$0.08 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$39.7M | -$40.8M | -$36.1M | -$40.7M | -$50.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -30.6% | -30.6% | -30.6% | -30.6% | -30.6% | -30.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 28.87 | 28.87 | 28.87 | 28.87 | 28.87 | 26.51 |
Key Ratios
ROA (TTM)
-29.4%
P/B
5.5
EPS (TTM)
$-1.58
CF/Share
$-1.39
52W High
$30.48
52W Low
$10.60
$10.60
52-Week Range
$30.48
Financial Health
Free Cash Flow
-$38.7M
Net Debt
-$57.2M
Cash
$61.1M
Total Debt
$4.0M
As of Dec 31, 2025
How does EWTX compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
EWTX valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
—
▼
0%
below
peers
(6.7)
vs Peers
vs Industry
Overvalued
P/B ratio
5.5
▲
5%
above
peers
(5.2)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
EWTX profitability vs Pharmaceuticals peers
ROE
-30.9%
▼
18%
below
peers
(-26.1%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-1.5%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(88.9%)
vs Peers
vs Industry
Top tier
ROA
-29.4%
▼
211%
below
peers
(-9.5%)
vs Peers
vs Industry
Weak
EWTX financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(27.4)
vs Peers
vs Industry
Low debt
Current ratio
26.5
▲
662%
above
peers
(3.5)
vs Peers
vs Industry
Strong liquidity
Beta
0.3
▼
56%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
EWTX fundamentals radar
EWTX
Peer median
Industry
EWTX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
EWTX vs peers: key metrics
Latest News
No related news yet